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Abstract
Background: Of all female genital tract tumors, 1-3% are stromal malignancies. In 8-10% of cases, these are
represented by Müllerian adenosarcoma an extremely rare tumor characterized by a stromal component of usually
low-grade malignancy and by a benign glandular epithelial component. Variant that arises in the pouch of Douglas
is scarcely mentioned in the medical literature.
Case Presentation: A 49-year-old para-0 woman, was seen at our OB/GYN-UNIT because she complained vaguely
of pelvic pain. She had a mass of undefined nature in the pouch of Douglas. A simple excision of the mass
showed low-grade Müllerian adenosarcoma with areas of stromal overgrowth. One and a half year after surgery, at
another hospital, a mass was detected in the patient’s posterior vaginal fornix and removed surgically. Six months
later she came back to our observation with vaginal bleeding and mass in the vaginal fornix. We performed radical
surgery. The pathological examination showed recurrent adenosarcoma. Surgical treatment was supplemented by
radiation therapy.
Conclusions: The case of Müllerian adenosarcoma reported here is the third known so far in the literature that
was located in the pouch of Douglas. To date, only two other such cases have been reported, including one
resulting from neoplastic degeneration of an endometriotic cyst.
Background
Malignant stromal tumors account for 1-3% of all
female genital tract tumors; 8-10% of these are Müller-
ian adenosarcomas. Adenosarcomas are rare tumors
scarcely reported in the medical literature that associate
benign glandular epithelium with a malignant endome-
trial stromal component of usually low histological
grade. Occasionally, a high-grade malignant stromal
component may raise a differential diagnosis issue with
leiomyosarcomas and carcinosarcomas [1,2].
Adenosarcomas arise more frequently in the uterus
[3], but cases with extrauterine locations in the ovaries
[4], cervix [5], vagina [6], and peritoneum [7] have also
been reported. Only two cases arising in the pouch of
Douglas are known so far [8]. The recurrence rate and
the medium- to long-term survival rate depend on the
grade and mitotic index of the stromal component
[9,10] and on the presence of sarcomatous overgrowth
[11]. Tumor location is also an important prognostic
factor as extragenital tumors have proved to be more
aggressive [8,12].
Of great interest is the association between adenosar-
coma and endometriosis, especially in extrauterine
forms, because the disease-free survival rate in endome-
triosis-associated tumors is far better than in unasso-
ciated mixed Müllerian tumors [13,14].
The standardization of treatment for extrauterine ade-
nosarcoma is difficult because of the limited clinical
experience and the variability of its presenting features.
Here we report the third known case of Müllerian
adenosarcoma located in the pouch of Douglas together
with a review of the literature.
Case Presentation
B.V., a 49-year-old para-0 woman, was seen at our Hospi-
tal’s Operating Unit because she complained vaguely of
pelvic pain, without any history of endometriosis. In her
past medical history, the patient reported appendectomy
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(Pap-smear, fecal occult blood test, bilateral mammogra-
phy and bilateral mammary echotomography) that she
underwent periodically were normal. During her hospital
stay, routine blood tests, a chest X-ray, and vaginal and
cervical smears were performed. The gynecological exami-
nation was normal, except for some mild pain on digital
exploration at the posterior vaginal fornix. There was no
vaginal bleeding. Transvaginal sonography revealed a 10 ×
6 cm mass of undefined nature in the pouch of Douglas.
Tumor marker tests indicated slightly elevated levels of
CA19-9 and CA125. The magnetic resonance imaging
(MRI) scan and the computed tomography (CT) scan
excluded any distant metastatic spread. Based on the
patient’s clinical picture, we advised radical surgery. She
accepted the surgical removal of the mass, but did not
agree to the recommended total hysterectomy, bilateral
adnexectomy, and pelvic lymphadenectomy. Therefore a
simple excision of the mass was planned. During surgery,
intraoperative frozen sections were performed that diag-
nosed a low-grade mesenchymal tumor to define better
after fixation and embedding.
The final slides showed a biphasic tumor associating
epithelial and stromal components. The epithelial com-
ponent was characterized by endometrial-type cells
without atypia showing a variety of metaplastic changes,
including ciliated and eosinophilic, that lined polypoid
vegetations, and glandular and phyllodes-like structures
(Figure 1A). The mesenchymal component was predo-
minantly represented by spindle cells with morphology
and immunophenotype similar to proliferative-phase
endometrial stroma (vimentin and CD10 positive (Figure
1B); S-100, desmin, H-caldesmon, calretinin, and inhibin
negative) and showing mild atypia. cells were arranged
in haphazard bundles and in dense periglandular cuffs
with intraglandular protrusions. In the latter areas, cells
had a mitotic index of 8/10 high-power fields (Figure
1C). Ki-67 proliferation index reached 30% in the most
active areas of the sarcomatous component. cells
showed high levels of positivity for both estrogen (80%)
and progesterone (90%) receptors. Pseudodecidualization
of the stroma was also observed in some areas (Figure
1D). Over 30% of the lesion consisted exclusively of
stromal proliferation devoid of any epithelial compo-
nent. These findings were consistent with a diagnosis of
low-grade Müllerian adenosarcoma with areas of stro-
mal overgrowth.
The post-operative course was uneventful and after a
few days the patient was discharged from hospital.
One and a half year after surgery, a mass was detected
in the patient’s posterior vaginal fornix. It was removed
surgically at another hospital unit and submitted for his-
tology, which confirmed a recurrence of low-grade Mül-
lerian adenosarcoma showing features similar to those
Figure 1 A. The primary tumor featured a phyllodes-like architecture dominated by an atypical hypercellular stroma forming
periglandular cuffs around glandular slit-like spaces lined by endometrial-type cells (4× magnification); B. The sarcomatous
component immunostained with CD-10 antibodies (10×) C. and showed scattered mitotic figures (40×); D. Areas of stromal
pseudodecidualization were also observed (20×).
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liferative activity of the tumor were observed as assessed
by Ki-67 staining. The patient chooses not to receive
any adjuvant therapy. Six months later she came back to
our observation with vaginal bleeding and a 4 cm poly-
poid mass in the posterior vaginal fornix. The MRI scan
and the CT scan excluded any metastatic disease. Piver’s
type-III radical hysterectomy with bilateral adnexectomy,
selective pelvic lymphadenectomy, and upper colpect-
omy were performed. Postoperative course regular, with-
out fever. The pathological examination showed
recurrent adenosarcoma infiltrating the uterus and the
posterior wall of the cervix (tumour dimensions: 4,5 ×
3 , 2×2 , 9c m ;w e i g h t :7 9g ) .T h ep a r a m e t r i aw e r en o t
involved. The recurrent tumor showed morphological
and antigenic features similar to the primary lesion. The
lymph node examination was negative for metastasis.
There was no evidence of endometriotic foci. Surgical
treatment was supplemented by radiation therapy in the
pelvic cavity with a total dose of 50 Gy.
Conclusions
Müllerian adenosarcoma is an uncommon mixed epithe-
lial-mesenchymal tumor of low-grade malignancy that
affects the female genital tract. In most cases, it occurs
in women aged 14 to 89 years (mean age, 58), is located
in the uterus and is accompanied by non-specific symp-
toms, i.e. vaginal bleeding, uterine enlargement, and
vague pelvic pain [15].
Since the first literature report by Clement and Scully
[1] in 1974, in spite of the low incidence of this tumor
investigators have been able to define its broad range of
features and their clinical and prognostic implications.
First of all, it is essential to provide a histological diagno-
sis of the lesion. Adenosarcoma should be distinguished
from its uncommon benign counterpart, adenofibroma,
but the differential diagnosis cannot be established with
certainty from curettage or biopsy specimens [8].
Histological criteria for malignancy include at least
mild atypia with a mitotic count of 2 per 10 HPF, dis-
tinctive periglandular cuffs of cellular stroma with or
without intraglandular protrusions of stromal element,
and invasion [1,11].
Heterologous differentiation is also found in 10-15% of
cases and helps in the differential diagnosis. Indeed, a
recent paper challenges the existence of adenofibroma,
as aggressive tumor behavior has also been reported in
cases without sarcomatous overgrowth and with only
mild nuclear atypia and a negligible mitotic rate [3].
Once the neoplastic transformation has been estab-
lished, the major factor affecting the outcome is tumor
location. In patients with genital tumors, disease recur-
rence occurs in about 25% of cases, usually in vagina or
in pelvis, with a mortality rate of about 10%. By contrast,
extragenital tumors are repo r t e dt or e c u ri no v e r5 0 %o f
cases and have a mortality rate of about 35% [12].
Extragenital tumors are distinctively less common and
are primarily located in the pelvic peritoneum, retroperi-
toneum, broad and round ligaments, vesicouterine
pouch, and rectouterine pouch. Only two cases of Mül-
lerian adenosarcoma located in the pouch of Douglas,
described by Ostor et al. [8] have been reported so far
(Table 1).
Clements and Scully [15] in 1990, in a large case series
of 100 uterine adenosarcomas, showed that recurrence
was strongly correlated to the degree of myometrial
invasion and that it primarily occurred in vagina, pelvis
and peritoneum, whereas hematogenous spread was
found only in two cases. In the Gynecologic Oncology
Group (GOG) study [10], 30% of women had a recur-
rence of the disease and 20% died over a mean follow-
up period of 38.3 months.
In this study, too, we were able to confirm a signifi-
cant correlation between extrauterine location or myo-
metrial invasion and recurrence rates. On the other
hand, the degree of myometrial invasion and the recur-
rence rate are strongly correlated to the differentiation
grade and the mitotic index of the sarcomatous stromal
component [9,11].
Sarcomatous overgrowth - as defined by a confluent
growth of the sarcomatous component occupying at least
one quarter of the tumor - and a deep muscular invasion
are considered adverse prognostic factors [9,13].
However, sarcomatous overgrowth is seen more fre-
quently in ovarian than in uterine tumors.
Ultimately, the most important negative prognostic
factors are lesion location, the degree of myometrial
invasion, and sarcomatous overgrowth. A further
strongly unfavorable prognostic factor is disease recur-
rence following primary treatment [11].
By contrast, a favorable prognostic factor in adenosar-
coma patients is the presence of endometriosis. The
possibility of a neoplastic transformation of endometrio-
tic foci has been suggested by several studies. In their
study, Stern et al. [14] (2001) investigated risk of neo-
plastic transformation in 1000 patients with endometrio-
sis. they observed that - as expected - endometrioid
adenocarcinoma was the most common histotype
among degenerative endometriotic lesions, followed -
quite unexpectedly - by adenosarcoma, with either ovar-
ian or extragenital location. However, most noteworthy
is the fact that in the literature there are reports about
cases with sarcomatous degeneration of long-standing
endometriotic lesions [4], which are associated with
absolute and disease-free survival rates that are consid-
erably higher than those for tumors unassociated with
endometriosis. This may be a consequence of lower
aggressiveness and a lower mitotic rate of the stromal
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found in these cases [12].
On immunohistochemical testing of endometriosis-asso-
ciated adenosarcoma, it is frequent to find positivity for
estrogen and progesterone hormone receptors. Soslow et
al. [16] (2008) also found a correlation with tamoxifen
hormone therapy in some forms that expressed progester-
one and estrogen receptors, suggesting that estrogen sti-
mulation is somehow involved in tumor pathogenesis, and
providing interesting biological clues to the possible effi-
cacy of hormone therapy. Hines et al. [17] (2002) reported
a case of extragenital adenosarcoma arising in an endome-
triotic lesion treated by surgical resection and adjuvant
therapy with medroxyprogesterone acetate. The 10-month
follow-up of this case did not show either residual disease
or recurrence, suggesting that medroxyprogesterone acet-
ate may be proposed as a useful drug in adjuvant hormone
therapy for advanced-stage tumors.
Notwithstanding the great progress made in the diagno-
sis and treatment of Müllerian adenosarcoma, its rarity
and its heterogeneous behavior make difficult to set up
well-defined therapeutic protocols. Given the risk of recur-
rence, metastasis and progression to high-grade sarcomas,
even low-grade tumors should be carefully considered
especially when associated with unfavorable risk factors.
As Müllerian adenosarcoma can evolve into the most
aggressive form of all mixed Müllerian tumors [18], i.e.
adenosarcomas with sarcomatous overgrowth and poorly
differentiated sarcoma not otherwise specified, small-size
low-grade malignant lesions with scarce myometrial
involvement should never be underestimated, in order
not to risk “undertreatment” with all its implications.
Radical surgery remains a therapeutic cornerstone. Shi
et al. [2] (2008) recommended a surgical approach simi-
lar to that used for the corresponding disease stages of
endometrial carcinoma. Total abdominal hysterectomy
with bilateral adnexectomy appears adequate for stage-I
patients. The decision of giving post-surgery chemother-
apy may be based on the extent of muscular invasion
and sarcomatous growth. While optimum treatment has
yet to be defined for stage-II patients, Guidozzi et al.
[19](2000) demonstrated that 34- to 56-month disease-
Table 1 Summary of cases of extragenital Müllerian adenosarcoma until 2003 and our case, modified from Murugasu
[21]
Authors Age Location Treatment Follow-up
Douglas
et al.
18 Retroperitoneum Chemotherapy Died after 10 wks with distant metastases
Bard et al. 46 Pelvic
peritoneum
Surgery, chemotherapy Died after 11 wks with distant metastases
Clement
et al.
45 Pelvic
peritoneum
Surgery, radiation therapy Pelvic recurrences; died after 9 mths
Clement
et al.
73 Pelvic
peritoneum
Surgery Died after 2 mths
Clement
et al.
58 Pelvic
peritoneum
Surgery Local recurrence at 15 mths; lung metastases at
45 mths
Kao &
Norris
42 Round ligament Partial surgery, chemotherapy, radiation therapy Died of disease after 10 mths
Russell et
al.
29 Broad ligament Surgery, radiation therapy Local recurrence at 5 mths; symptom free; died
of melanoma after 9 yrs
Vara et al. 62 Bladder Surgery Disease free at 1 yr
Roman et
al.
63 Retroperitoneum Surgery, chemotherapy, radiation therapy Multiple recurrences; heart and liver metastases;
died of disease after 10 yrs
Kerner et
al.
32 Broad ligament Surgery Pelvic recurrences at 22 mths
De Jonge
et al.
16 Pelvic
peritoneum
Surgery, chemotherapy Disease free at 57 mths
Kato et al. 20 Peritoneum Surgery Disease free at 1 yr
Visvalinga
et al.
50 Pelvic
peritoneum
Surgery, chemotherapy Died of disease after1 yr
Ostor et
al.
49 Pouch of
Douglas
Surgery, chemotherapy, radiation therapy Alive with disease at 18 mths
Morugasu
et al.
23 Pouch of
Douglas
Surgery, chemotherapy, radiation therapy Disease free at 1 yr
Present
case
49 Pouch of
Douglas
- First step: partial surgery; - Second step (after 24 mths):
radical surgery and radiation therapy
Local multiple recurrences (after 18 and 24
mths), today disease free
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by neoadjuvant radiation therapy followed by radical
surgery and then again by adjuvant radiation therapy
followed by three chemotherapy cycles with carboplati-
num and farmarubicin. Huang et al. [12] (2009) pro-
posed treatment with ifosfamide and cisplatinum in the
extragenital forms with high sarcomatous growth. Del
Carmen et al. [20] (2003) suggested that patients should
be treated with liposomal doxorubicin, which is well tol-
erated and effective, both in post-surgical recurrences
and as adjuvant therapy in extragenital forms. Notwith-
standing the success obtained in reducing the tumor
mass, however, in the case reported by these authors the
tumor’s highly aggressive behavior led to a rapid
resumption of growth at treatment discontinuation and
the patient eventually died after 29 months from diag-
nosis and 20 months from treatment.
Thus, while awaiting to acquire a wider clinical experi-
ence on this rare form of genital tumor, we recommend
a “customized” treatment that uses surgery and either
neoadjuvant or adjuvant chemo/radiation therapy,
which, in the event of early diagnosis, can be expected
to achieve a disease-free result.
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